Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

Emeryk, Andrzej; Emeryk-Maksymiuk, Justyna

doi:10.5603/arm.a2020.0132

Cited by 9 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies suggest that fenoterol may be 25 times more potent than salbutamol at the site of action. Like other β2-agonists, fenoterol exhibits a rapid onset of action (within 5–15 min) and a relatively short duration of action (3–4 h) [ 14 ].…”

Section: Therapeutic Class Overview Of Short-acting Bronchodilatorsmentioning

confidence: 99%

“…This results in a gradual decrease in the bronchodilator effect of SABA, leading to less effective symptom relief. While the precise causes of SABA tachyphylaxis are still being elucidated, several potential mechanisms have emerged, such as the downregulation of β2-ARs, the desensitization of G protein-coupled signaling, and the refractory period of ASM cells [ 10 , 14 ].…”

Section: Therapeutic Class Overview Of Short-acting Bronchodilatorsmentioning

confidence: 99%

See 1 more Smart Citation

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Licari,

Manti,

Mastellone

et al. 2024

Ital J Pediatr

View full text Add to dashboard Cite

Short-acting bronchodilators are a class of medications commonly used to treat asthma, chronic obstructive pulmonary disease, and other respiratory conditions. The use of these medications has evolved over time as we have gained a better understanding of their effectiveness and safety in the pediatric population. This comprehensive review synthesizes the current understanding of short-acting β2-agonists and short-acting anticholinergics in children. It addresses indications, contraindications, safety considerations, and highlights areas where further research is needed to guide the most effective use of short-acting bronchodilators.

show abstract

Section: Therapeutic Class Overview Of Short-acting Bronchodilatorsmentioning

confidence: 99%

Section: Therapeutic Class Overview Of Short-acting Bronchodilatorsmentioning

confidence: 99%

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Licari,

Manti,

Mastellone

et al. 2024

Ital J Pediatr

View full text Add to dashboard Cite

show abstract

“…Common adverse effects include skeletal muscle tremor, headache, tachycardia, tachycardia, palpitations and hypokalemia. Elevated plasma levels of lactic acid (lactic acidosis) have also been reported [2][3]. Of concern, bronchospasm may occur in rare cases following inhalation of short-acting beta2 agonists [1,4].No cases have been reported in the Chinese population.Current literature mentions that the short-acting β2adrenoceptor agonists salbutamol, levosalbutamol, terbutaline, ipratropium bromide, salmeterol, and pirbuterol can cause paradoxical bronchospasm [5][6][7][8][9][10], with salbutamol being more common and terbutaline being rare.…”

Section: Introductionmentioning

confidence: 99%

Tremor and Paradoxical bronchospasm caused by Terbutaline

Wang¹,

Liu²,

Liang³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Common adverse reactions of terbutaline include skeletal muscle tremor, headache,tachycardia, palpitations, hypokalemia and so on.Bronchospasm caused by terbutaline is rarely reported. This article reports one case of severe bronchospasm caused by nebulized terbutaline sulfate inhalation therapy. Case presentation A 51-year-old female patient was admitted to hospital with acute bronchitis.The main complaints were cough, sputum and wheezing. She has no history of drug or food allergies. On the day of admission, terbutaline nebulization treatment immediately caused limb tremor and bronchospasm. After glucocorticoid, aminophylline, non-invasive respiratory support and other symptomatic treatments,the patient improved on the 4th day. Conclusion The mechanism of terbutaline leading to bronchospasm is still unclear. The tert-butylline on the chemical structure of terbutaline may bind to proteins to produce IgE-mediated bronchospasm, The excipient ededidine disodium and the osmotic pressure of the nebulized diluent may also lead to bronchospasm. During the clinical treatment, hypotonic nebulizing dilutions should be avoided, and close monitor should be taken in case ofpossible fatal bronchospasm.

show abstract

“…Albuterol, a short-acting beta-2 agonist (SABA) and bronchodilator, is one of the most used asthma medications in both children and adults ( 3 ). β2-agonists promote bronchodilation by activating β2-adrenergic receptors (β2ARs) on airway smooth muscle cells, resulting in decreased bronchoconstriction via increases in cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Circulating MicroRNAs associated with Bronchodilator Response in Childhood Asthma

Sharma,

Tiwari,

Kho

et al. 2023

Preprint

View full text Add to dashboard Cite

Rationale: Bronchodilator response (BDR) is a measure of improvement in airway smooth muscle tone, inhibition of liquid accumulation and mucus section into the lumen in response to short-acting beta-2 agonists that varies among asthmatic patients. MicroRNAs (miRNAs) are well-known post-translational regulators. Identifying miRNAs associated with BDR could lead to a better understanding of the underlying complex pathophysiology. Objective: The purpose of this study is to identify circulating miRNAs associated with bronchodilator response in asthma and decipher possible mechanism of bronchodilator response variation. Methods: We used available small RNA sequencing on blood serum from 1,134 asthmatic children aged 6 to 14 years who participated in the Genetics of Asthma in Costa Rica Study (GACRS). We filtered the participants into high and low bronchodilator response (BDR) quartiles and used DeSeq2 to identify miRNAs with differential expression (DE) in high (N= 277) vs low (N= 278) BDR group. Replication was carried out in the Leukotriene modifier Or Corticosteroids or Corticosteroid-Salmeterol trial (LOCCS), an adult asthma cohort. The putative target genes of DE miRNAs were identified, and pathway enrichment analysis was performed. Results: We identified 10 down-regulated miRNAs having odds ratios (OR) between 0.37 and 0.76 for a doubling of miRNA counts and one up-regulated miRNA (OR=2.26) between high and low BDR group. These were assessed for replication in the LOCCS cohort, where two miRNAs (miR-200b-3p and miR-1246) were associated. Further, functional annotation of 11 DE miRNAs were performed as well as of two replicated miRs. Target genes of these miRs were enriched in regulation of cholesterol biosynthesis by SREBPs, ESR-mediated signaling, G1/S transition, RHO GTPase cycle, and signaling by TGFB family pathways. Conclusion: MiRNAs miR-1246 and miR-200b-3p are associated with both childhood and adult asthma BDR. Our findings add to the growing body of evidence that miRNAs play a significant role in the difference of asthma treatment response among patients as it points to genomic regulatory machinery underlying difference in bronchodilator response among patients. Trial registration: LOCCS cohort [ClinicalTrials.gov number: NCT00156819], GACRS cohort [ ClinicalTrials.gov number: NCT00021840]

show abstract

Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

Cited by 9 publications

References 29 publications

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases

Tremor and Paradoxical bronchospasm caused by Terbutaline

Circulating MicroRNAs associated with Bronchodilator Response in Childhood Asthma

Contact Info

Product

Resources

About